SPYRE THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-03-31 was $18.00K, a 90.22% decline year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-09-30 was $38.00K, a 83.48% decline year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-03-31 was $184.00K, a 17.86% decline year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2021-09-30 was $230.00K, a 19.79% increase year-over-year.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $222.00K, a 51.10% decline from fiscal 2021.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $454.00K, a 24.04% increase from fiscal 2020.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $366.00K, a 19.22% increase from fiscal 2019.
- SPYRE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2019 was $307.00K, a 48.31% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2023-03-31 | $18.00K 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | $222.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $38.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $184.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $454.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | $230.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $224.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $366.00K 10-K · filed 2023-03-02 | |
| 2020-09-30 | $192.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $174.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $307.00K 10-K · filed 2022-03-08 | |
| 2019-09-30 | $164.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $143.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $207.00K 10-K · filed 2021-03-18 | |
| 2018-09-30 | $129.00K 10-Q · filed 2019-11-06 | |
| 2018-03-31 | $78.00K 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $131.00K 10-K · filed 2020-02-24 | |
| 2016-12-31 | $76.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |